Table 2.

Significant Logistic regression of mortality on dose candidate. CoP: [(Est/SE)/(P-Value)]

Criteria	NiVB ELISA Titer on Study Day 21	NiVM ELISA Titer on Study Day 21	NiVB FRNT50	NiVM FRNT50
Treatment (Dose) affecting endpoint	(2.16)/(0.032)	(2.16)/(0.032)	(2.16)/(0.032)	(2.16)/(0.032)
Treatment (Dose) affecting CoP	(5.12)/( < 0.0001)	(5.15)/( < 0.0001)	(6.21)/( < 0.0001)	(7.48)/(0.0001)
CoP affecting endpoint	(2.17)/(0.027)	(2.00)/(0.046)	(2.23)/(0.026)	(2.37)/(0.018)
Treatment offers no more information than CoPa	0.028/0.85	0.10/0.37	0.06/0.14	0.06/0.48

a.- Summary P-Values for Correlate of Protection (CoP) and Dose (CoP/Dose).